Justin T Puckett (Justin Puckett)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 6

Top Topics

Chronic Lymphocytic Leukemia

Top Venues

Cancer medicine

Future oncology (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Scott F Huntington, Enrico de Nigris, Justin T Puckett, Sachin Kamal-Bahl, Mohammed Farooqui, Katherine Ryland, Eric M Sarpong, Siyang Leng, Xiaoqin Yang, Jalpa A Doshi
Real-world analysis of adverse event rates after initiation of ibrutinib among Medicare beneficiaries with chronic lymphocytic leukemia. Cancer medicine 13 (2) (2024)
Scott F Huntington, Enrico de Nigris, Justin T Puckett, Sachin Kamal-Bahl, Mohammed Farooqui, Katherine Ryland, Eric M Sarpong, Siyang Leng, Xiaoqin Yang, Jalpa A Doshi
Real-world analysis of adverse event rates after initiation of ibrutinib among Medicare beneficiaries with chronic lymphocytic leukemia. Cancer medicine 13 (2) (2024)
Scott F Huntington, Enrico de Nigris, Justin T Puckett, Sachin Kamal-Bahl, Mohammed Farooqui, Katherine Ryland, Eric M Sarpong, Siyang Leng, Xiaoqin Yang, Jalpa A Doshi
Real-world analysis of adverse event rates after initiation of ibrutinib among Medicare beneficiaries with chronic lymphocytic leukemia. Cancer medicine 13 (2) (2024)
Scott F Huntington, Enrico de Nigris, Justin T Puckett, Sachin Kamal-Bahl, Mohammed Farooqui, Katherine Ryland, Eric M Sarpong, Siyang Leng, Xiaoqin Yang, Jalpa A Doshi
Real-world analysis of adverse event rates after initiation of ibrutinib among Medicare beneficiaries with chronic lymphocytic leukemia. Cancer medicine 13 (2) (2024)
Mahek Garg, Justin T Puckett, Sachin Kamal-Bahl, Monika Raut, Katherine Elizabeth Ryland, Jalpa A Doshi, Scott F Huntington
Real-world treatment patterns, survival, health resource use and costs among Medicare beneficiaries with diffuse large B-cell lymphoma. Future oncology (London, England) (2023)
Sachin Kamal-Bahl, Justin T Puckett, Indranil Bagchi, Ellen Miller-Sonet, Scott F Huntington
Barriers and solutions to improve access for chimeric antigen receptor therapies. Immunotherapy (2022)